Clinical Trials Logo

Breast Cancer clinical trials

View clinical trials related to Breast Cancer.

Filter by:

NCT ID: NCT05914402 Recruiting - Breast Cancer Clinical Trials

Axillary Surgery De-escalation After Neoadjuvant Therapy Using Dedicate Breast PET

NeoaPET
Start date: June 18, 2023
Phase: N/A
Study type: Interventional

Some breast cancer patients with initial axillary metastasis can achieve axillary complete pathological remission(A-pCR) after neoadjuvant therapy(NAT),These patients are candidates for axillary Surgery de-escalation. This prospective study is designed to evaluate the feasibility and safety of axillary surgery de-escalation for the initial axillary metastasis breast cancer patients who are predicted to achieve A-pCR using multiple pathological indicators and imaging examinations (molecular typing, ultrasound and dedicated breast positron emission tomography, etc.) before and after 1-2 cycles NAT

NCT ID: NCT05914168 Recruiting - Breast Cancer Clinical Trials

Clinical Data Collection in Breast Tomosynthesis (COBRIS)

COBRIS
Start date: February 15, 2023
Phase: N/A
Study type: Interventional

The purpose of the study is to assess an image acquisition application for breast tomosynthesis in a clinical environment

NCT ID: NCT05913713 Recruiting - Breast Cancer Clinical Trials

HIIT Following Breast Cancer Chemotherapy

Start date: March 7, 2024
Phase: N/A
Study type: Interventional

Chemotherapy is an effective breast cancer treatment, which helped to increase the 5-year survival rate to approximately 95%. However, breast cancer survivors have a higher risk of cardiovascular disease (CVD) due to chemotherapy than adults without cancer. Cardiovascular rehabilitation can be an effective strategy to decrease the incidence of CVD and its risk factors in this population. The proposed study may help to examine the effect and durability of a novel high-intensity interval training compared to moderate-intensity continuous training on cardiovascular rehabilitation in breast cancer survivors.

NCT ID: NCT05913440 Recruiting - Breast Cancer Clinical Trials

HER2-low Unresectable and/or Metastatic Breast Cancer in Russia

Start date: May 30, 2023
Phase:
Study type: Observational

Planned study population consists of approximately 3,150 adult patients with HER2-negative (IHC 0, + or IHC2+/ISH-) unresectable or metastatic BC enrolled to the study in order to obtain approximately 2,000 patients with confirmed HER2 low status (IHC1+ or IHC2+/ISH ).

NCT ID: NCT05912933 Not yet recruiting - Breast Cancer Clinical Trials

A Study to Learn About the Relationship Between Hepatic Impairment and Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal-bow-sai-klib)

Start date: March 1, 2024
Phase:
Study type: Observational

The purpose of this study is to evaluate incidence of grade 4 neutropenia in patients who have hepatic impairment and use the study medicine Palbociclib. This study is seeking participants: - treated with the study medicine Palbociclib - having any breast cancer records in same month as the index date (the first prescription date) - having prescription records of palbociclib from 20 December 2016 to 29 February 2024 The study design is a cohort study. This study design uses de-identified patient data from a hospital based electronic medical record and claim database in Japan. One of the important side effects of taking Palbociclib is neutropenia (decreased count of neutrophils - a type of white blood cell). In this study, the relationship between neutropenia caused by Palbociclib and hepatic impairment was studied after it was released to the market. To do that, the study gathered details of breast cancer patients newly treated with Palbociclib from 23 hospitals and 10 medical institutes across Japan. The below patient details were collected: - dose of Palbociclib - other medicines prescribed for cancer - age - gender - past information on cancer treatments - laboratory findings at baseline The result was based on the neutrophil count collected from the laboratory data. Around 1300 patients newly treated with Palbociclib for breast cancer was calculated by the medical information database network (MID-NET) in 6 years from 15 December 2017.

NCT ID: NCT05912231 Recruiting - Breast Cancer Clinical Trials

Ultrahypofractionation and Normal Tissue Toxicity

Start date: August 15, 2023
Phase: N/A
Study type: Interventional

This research is being done to see if proton beam radiation therapy (PBT) results in fewer changes to a participant's heart measured with MRI-imaging than conventional or "photon" radiation therapy (XRT) for participants with non-metastatic left sided breast cancer. The names of the two study groups in this research study are: - Proton Radiation Therapy (PBT) - Conventional or "Photon" Radiation Therapy (XRT)

NCT ID: NCT05912062 Recruiting - Breast Cancer Clinical Trials

Early On-treatment Transcriptional Profiling as Predictor of Response in Early-stage HER2-positive Breast Cancer

BiOnHER
Start date: March 22, 2021
Phase:
Study type: Observational

Non-randomized, open label, translational research study in women with early HER2-positive invasive breast carcinoma eligible for neoadjuvant treatment. The aim of BIONHER is to assess the impact of short-term neoadjuvant dual HER2-blockade on HER2-positive breast cancer transcriptomic profile and to evaluate whether early on treatment tumor biopsy can improve the accuracy of predicting response over the pre-treatment alone.

NCT ID: NCT05911867 Recruiting - Breast Cancer Clinical Trials

Muscle Energy Technique and Mulligan's Mobilization in Breast Cancer Surgery Patients

MWMMET
Start date: June 1, 2023
Phase: N/A
Study type: Interventional

A recent study aimed to examine the combined effect of Mulligan and muscle energy techniques on postural changes and shoulder kinematics among women who had undergone breast cancer surgery with axillary dissection.

NCT ID: NCT05910398 Recruiting - Clinical trials for Breast Cancer Invasive

Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer

CORINNE-PI
Start date: June 1, 2023
Phase: Phase 3
Study type: Interventional

This is a prospective, randomised, controlled, multicentre study to compare the efficacy and safety between continuous or intermittent extension of adjuvant pyrotinib in invasive human epidermal growth factor receptor 2 (HER2)-positive breast cancer.

NCT ID: NCT05909813 Completed - Breast Cancer Clinical Trials

Individualized Piano Instruction (IPI) for Improving Cognition in Breast Cancer Survivors.

Start date: January 8, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to test the study method and procedure for individualized piano instruction (IPI) and its impact on chemotherapy related cognitive impairment (CRCI) symptoms. There have been studies that show the benefits of leaning to play the piano keyboard on cognitive skills in children and elderly populations. The information collected from the program will be used to examine the feasibility of implementing this program permanently